BEIGENE,LTD.Files An 8-K Other Events

17

BEIGENE,LTD.Files An 8-K Other Events

Item 8.01 Other Events

On June14, 2017, BeiGene,Ltd. (the Company) issued a press
release announcing updated clinical data from the ongoing Phase 1
trial of its Brutons Tyrosine Kinase (BTK) inhibitor BGB-3111 in
patients with chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) in a poster at the 14th International
Conference on Malignant Lymphoma (14-ICML) in Lugano,
Switzerland. The full text of the Companys press release is filed
as Exhibit99.1 to this Current Report on Form8-K and is
incorporated herein by reference.

On June15, 2017, the Company issued a press release announcing
updated data from the ongoing Phase 1 trial of its BTK inhibitor
BGB-3111 in patients with Waldenstrms macroglobulinemia presented
at 14-ICML. The full text of the Companys press release is filed
as Exhibit99.2 to this Current Report on Form8-K and is
incorporated herein by reference.

On June16, 2017, the Company issued a press release announcing
initial clinical data from the ongoing Phase 1 trial of its BTK
inhibitor BGB-3111 combined with the anti-CD20 antibody
obinutuzumab in patients with CLL or SLL and follicular lymphoma
presented at 14-ICML. The full text of the Companys press release
is filed as Exhibit99.3 to this Current Report on Form8-K and is
incorporated herein by reference.

Item 9.01 Financial Statements and
Exhibits

(d) Exhibits.

ExhibitNo.

Description

99.1

Press Release issued on June14, 2017

99.2

Press Release issued on June15, 2017

99.3

Press Release issued on June16, 2017

***




BeiGene, Ltd. Exhibit
EX-99.1 2 a17-15290_1ex99d1.htm EX-99.1 Exhibit 99.1     BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma   CAMBRIDGE,…
To view the full exhibit click here

An ad to help with our costs